In this issue:
PrEP with generic TDF/FTC
Benefits and risks of rapid ART initiation
Tenofovir-associated nephrotoxicity
Itraconazole or amphotericin B for HIV-associated talaromycosis
Lopinavir plus NRTI vs lopinavir plus raltegravir for second-line treatment
Abacavir and risk of recurrent myocardial infarction
ART regimens and AIDS-defining neurological conditions
Concomitant medication polypharmacy and ART
Metabolic comorbidities in HIV outpatients
Frailty phenotype/frailty index and clinical outcomes
Please login below to download this issue (PDF)